Clinical trial
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered…
NCT00432042 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00432042 |
|---|---|
| Title | Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) |
| Official title | An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant Versus Separate Administration of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) and a Booster Dose of Infanrix® Hexa in Healthy Children 12 to 23 Months of Age |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Varicella, Measles, Mumps, Rubella, Diphtheria, Tetanus, Pertussis, Poliomyelitis, Hepatitis B, Haemophilus Infections |
| Intervention type | Biological |
| Interventions | ProQuad®, Infanrix® hexa |
| Enrollment | 955 |
| Start date | Jan 12, 2007 |
| Primary completion | Mar 27, 2008 |
| Completion | Mar 27, 2008 |
| First posted | Feb 6, 2007 |
| Last update posted | Mar 19, 2018 |
| Countries | Germany, Italy |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: